Company profile
Infinity Pharmaceuticals, Inc.
OTC: INFIQ · Healthcare · Biotechnology
#769 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 46GM —SS 47
v0.1 · 25/100 weight · pillars only
↑ listing tenure, revenue growth (YoY) · ↓ market scale, operating margin
Methodology →Revenue TTM
$2.6M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$44.4M
Employees
30
as of 2026-08-03
Market cap
$9.1k
as of 2026-08-03
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.6M$2.6M2022
Net income-$44.4M-$44.4M2022
Operating income-$44.8M-$44.8M2022
Total assets$42.2M$42.2M2022
Liabilities$61.2M$61.2M2022
Equity-$19.1M-$19.1M2022
Revenue trend
FY2018 – FY2022 · USD
FY18
FY18
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Infinity Pharmaceuticals, Inc.’s revenue?
Infinity Pharmaceuticals, Inc. booked $2.6M in FY2022 revenue, growing 40% year over year — faster than most Healthcare companies we track, at a -1711.1% net margin.
Peers · Healthcare
Hypha Labs, Inc.35DQHSLab, Inc.70BInnovative Eyewear, Inc.44DENvue Medical, Inc.46DFiore Cannabis Ltd.——GeoVax Labs, Inc.38DNeighbors
Middlesex →Key facts
CEOVishal Mehta
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeOTC: INFIQ
Employees30
IPO date2000-07-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.